Wei Lin 4
4 · Revolution Medicines, Inc. · Filed Sep 18, 2025
Insider Transaction Report
Form 4
Wei Lin
Chief Medical Officer
Transactions
- Sale
Common Stock
[F1][F2]2025-09-16$45.82/sh−2,160$98,982→ 88,339 total
Footnotes (2)
- [F1]Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on December 23, 2024 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after March 15, 2025.
- [F2]Includes 58,850 restricted stock units.
Signature
/s/ Jack Anders, as Attorney-in-fact for Wei Lin|2025-09-18